A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study
Allergy2015Vol. 71(1), pp. 99–107
Citations Over TimeTop 10% of 2015 papers
Oliver Pfaar, Esther van Twuijver, J. D. Boot, Dirk Jan E. Opstelten, L. Klimek, Ronald van Ree, Zuzana Diamant, Piotr Kuna, Petr Panzner
Abstract
A multicentre trial evaluated the dose-response and tolerability of SB. All active treatment groups showed better responses than placebo for both primary and secondary parameters. The results indicate that, within the studied dose range, SB 40,000 AUN/ml is the most optimal effective and safe dose (ClinicalTrials.gov: NCT01639768).
Related Papers
- → Clinical efficacy of sublingual‐swallow immunotherapy: a double‐blind, olacebo‐controlled trial of a standardized five‐grass‐pollen extract in rhinitis(1998)179 cited
- → Efficacy and safety of high‐doses sublingual immunotherapy in ultra‐rush scheme in children allergic to grass pollen(2009)94 cited
- → Subcutaneous Versus Sublingual Immunotherapy for Allergic Rhinitis and/or Asthma(2011)26 cited
- → Shorter Dosing Intervals of Sublingual Immunotherapy Lead to More Efficacious Treatment in a Mouse Model of Allergic Inflammation(2010)15 cited
- → Sublingual and oral immunotherapy(2004)15 cited